Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

Genmab said 22 abstracts on epcoritamab will be presented or published at the American Society of Hematology’s December 12–15, 2026, meeting. Six are oral presentations, including the first data disclosure from Phase 3 EPCORE DLBCL-4, which evaluates epcoritamab with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma; the release provides no study results.

Analysis

The release creates a dated catalyst, not yet an earnings revision: the investment question is whether EPCORE DLBCL-4 produces efficacy and safety that can support use in a broader, earlier-treated population. A positive readout could extend the commercial runway for epcoritamab and strengthen Genmab’s bargaining position in its collaboration with AbbVie; the same data could also raise the bar for competing lymphoma regimens. But 22 abstracts are not 22 independent value inflection points, and the announced breadth is company framing rather than evidence of clinical differentiation.

Near term, expect attention to build into the December 12–15 ASH meeting, with event volatility concentrated around the DLBCL-4 disclosure. Over 1–3 months, assess response durability, safety (especially infections/cytopenias), treatment discontinuations, and whether the combination’s benefit is clinically meaningful versus available options—not headline response rates alone. Over 6–18 months, earlier-line adoption would matter only if follow-up supports durable benefit and the regimen can compete on tolerability, convenience, and treatment economics. The thesis fails on weak durability, material safety burden, or no credible differentiation; verify the full abstract and comparator context before changing estimates.

Key Decisions for Investors

• Treat GMAB as a catalyst watch rather than buying on abstract count alone. Review the full DLBCL-4 data at ASH before underwriting an earlier-line revenue contribution.
• For event-oriented exposure, consider only a small, defined-risk GMAB call spread ahead of the data if implied volatility and spread pricing are reasonable; avoid naked calls into the binary readout. No options recommendation without checking current pricing and liquidity.
• Track the readout for durability, adverse-event discontinuations, and treatment burden alongside response metrics. A strong headline response without durable or tolerable benefit is not enough to support a sustained re-rating.
• Falsification: materially disappointing durability or safety, or subsequent company commentary that fails to support broader-line development. Conversely, differentiated and durable benefit with manageable safety would justify reassessing the commercial runway and AbbVie collaboration contribution.